Market Cap 1.56B
Revenue (ttm) 605.22M
Net Income (ttm) -168.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27.86%
Debt to Equity Ratio 0.28
Volume 1,061,500
Avg Vol 1,522,070
Day's Range N/A - N/A
Shares Out 111.80M
Stochastic %K 51%
Beta 0.75
Analysts Strong Sell
Price Target $27.19

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic ca...

Industry: Medical Devices
Sector: Healthcare
Address:
Neuhofstrasse 21, Baar, Switzerland
rvc01
rvc01 Oct. 24 at 7:04 PM
$NVCR WOW! What a market!!! Everything is up...well, almost everything. LOL
0 · Reply
kamilaponce17
kamilaponce17 Oct. 24 at 3:12 PM
$NVCR — Biotech innovation with real clinical potential. $NVCR could benefit from healthcare investment trends through 2030.
0 · Reply
vicenterivas
vicenterivas Oct. 23 at 6:46 PM
$NVCR showing some strength. Healthcare can rally too 💊
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 23 at 6:19 PM
$SNDX FY2026 & 10-year revenue multiple versus all commercial-stage oncology focused bios with market caps over $1.0B. SNDX's cumulative 10-year analyst revenue estimate excludes the highest revenue forecast for all 10-years. Using actual analyst consensus, SNDX trades at 0.12X 10-year revenues. Valuations use intra-day share prices on 10/23/2025 $IBRX trades at the 2nd lowest multiple. However, we understand IBRX needs future clinical wins to realize those estimates. We are not 100% certain $PGEN belongs in this peer group. Any suggestions would be welcome. $JAZZ multiples use enterprise value. $NVCR also appears a value using analyst estimates & multiples versus peers. We understand ST users express doubts on whether analyst estimates are credible in light of lung related sales to date. This is not investment advice.
3 · Reply
scotofool
scotofool Oct. 21 at 6:29 PM
$NVCR blokes $NVCR bandooglizing wee investors, fakey results to authoritys, proper cock-up, target 7
1 · Reply
buylowandwait
buylowandwait Oct. 20 at 6:14 PM
$NVCR It is in management's hand to show that multi-indication franchise actually means sth from revenue point of view ! The Metis P3 trial results have been available for more than 1 years, but we still don't know if FDA filing was done ! Patiently waiting for Q3 results to understand what management has done for the company. This is my worst performer for the year, and I hope next two years, the dog turns around, and it truly has the potential.
2 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN Oct. 20 at 3:48 PM
$NVCR Additional (post-doc) Panova-3 analysis from ESMO (yesterday). My read: If patients actually wear the TTF arrays, they do much better (no surprise)! Data for the fist 3 months of usage shows: Wear TTF arrays >50% of the time, mOS = 17.1 months Wear TTF arrays < 50% of the time, mOS = 13.8 months Interesting to note: 166 patients wore arrays > 50% of time in 1st 3 months, while 107 patients wore the device <50% of the time. Remember target compliance = wearing arrays 75%. So more than a 1/3 of the patients in the TTF arm of the trial barely wore the arrays at all, and the trial still hit its endpoint.
4 · Reply
GoBigRed19
GoBigRed19 Oct. 18 at 3:13 AM
0 · Reply
BB_88_
BB_88_ Oct. 17 at 7:41 PM
$NVCR 13.8 should crack shortly
0 · Reply
BB_88_
BB_88_ Oct. 17 at 7:26 PM
$NVCR bullish long term but took a 13.9 short in to close
1 · Reply
Latest News on NVCR
NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum

Oct 17, 2025, 7:55 AM EDT - 8 days ago

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum


Novocure to Report Third Quarter 2025 Financial Results

Oct 1, 2025, 7:00 AM EDT - 24 days ago

Novocure to Report Third Quarter 2025 Financial Results


Novocure Announces Upcoming Investor Events

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Novocure Announces Upcoming Investor Events


NovoCure's Wearable Oncology Edge And Compelling Valuation

Jul 30, 2025, 12:47 AM EDT - 3 months ago

NovoCure's Wearable Oncology Edge And Compelling Valuation


Top 3 Health Care Stocks That May Explode In July

Jul 28, 2025, 6:52 AM EDT - 3 months ago

Top 3 Health Care Stocks That May Explode In July

HCA MOH


NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

Jul 25, 2025, 4:49 PM EDT - 3 months ago

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript


Novocure Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 7:00 AM EDT - 3 months ago

Novocure Reports Second Quarter 2025 Financial Results


Novocure to Report Second Quarter 2025 Financial Results

Jun 30, 2025, 7:00 AM EDT - 4 months ago

Novocure to Report Second Quarter 2025 Financial Results


NovoCure: Loading Up On Growth Catalysts

May 24, 2025, 3:12 AM EDT - 5 months ago

NovoCure: Loading Up On Growth Catalysts


NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 10:34 AM EDT - 6 months ago

NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript


Novocure Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 6 months ago

Novocure Reports First Quarter 2025 Financial Results


Novocure to Report First Quarter 2025 Financial Results

Apr 1, 2025, 7:00 AM EDT - 7 months ago

Novocure to Report First Quarter 2025 Financial Results


NovoCure Q4 2024 Earnings: Strong And Growing Pipeline

Feb 28, 2025, 1:10 PM EST - 8 months ago

NovoCure Q4 2024 Earnings: Strong And Growing Pipeline


Novocure to Participate in Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 11 months ago

Novocure to Participate in Upcoming Investor Conferences


Novocure Reports Third Quarter 2024 Financial Results

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Novocure Reports Third Quarter 2024 Financial Results


NovoCure: There Is Still More Upside

Oct 16, 2024, 11:00 AM EDT - 1 year ago

NovoCure: There Is Still More Upside


Novocure to Report Third Quarter 2024 Financial Results

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Novocure to Report Third Quarter 2024 Financial Results


rvc01
rvc01 Oct. 24 at 7:04 PM
$NVCR WOW! What a market!!! Everything is up...well, almost everything. LOL
0 · Reply
kamilaponce17
kamilaponce17 Oct. 24 at 3:12 PM
$NVCR — Biotech innovation with real clinical potential. $NVCR could benefit from healthcare investment trends through 2030.
0 · Reply
vicenterivas
vicenterivas Oct. 23 at 6:46 PM
$NVCR showing some strength. Healthcare can rally too 💊
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 23 at 6:19 PM
$SNDX FY2026 & 10-year revenue multiple versus all commercial-stage oncology focused bios with market caps over $1.0B. SNDX's cumulative 10-year analyst revenue estimate excludes the highest revenue forecast for all 10-years. Using actual analyst consensus, SNDX trades at 0.12X 10-year revenues. Valuations use intra-day share prices on 10/23/2025 $IBRX trades at the 2nd lowest multiple. However, we understand IBRX needs future clinical wins to realize those estimates. We are not 100% certain $PGEN belongs in this peer group. Any suggestions would be welcome. $JAZZ multiples use enterprise value. $NVCR also appears a value using analyst estimates & multiples versus peers. We understand ST users express doubts on whether analyst estimates are credible in light of lung related sales to date. This is not investment advice.
3 · Reply
scotofool
scotofool Oct. 21 at 6:29 PM
$NVCR blokes $NVCR bandooglizing wee investors, fakey results to authoritys, proper cock-up, target 7
1 · Reply
buylowandwait
buylowandwait Oct. 20 at 6:14 PM
$NVCR It is in management's hand to show that multi-indication franchise actually means sth from revenue point of view ! The Metis P3 trial results have been available for more than 1 years, but we still don't know if FDA filing was done ! Patiently waiting for Q3 results to understand what management has done for the company. This is my worst performer for the year, and I hope next two years, the dog turns around, and it truly has the potential.
2 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN Oct. 20 at 3:48 PM
$NVCR Additional (post-doc) Panova-3 analysis from ESMO (yesterday). My read: If patients actually wear the TTF arrays, they do much better (no surprise)! Data for the fist 3 months of usage shows: Wear TTF arrays >50% of the time, mOS = 17.1 months Wear TTF arrays < 50% of the time, mOS = 13.8 months Interesting to note: 166 patients wore arrays > 50% of time in 1st 3 months, while 107 patients wore the device <50% of the time. Remember target compliance = wearing arrays 75%. So more than a 1/3 of the patients in the TTF arm of the trial barely wore the arrays at all, and the trial still hit its endpoint.
4 · Reply
GoBigRed19
GoBigRed19 Oct. 18 at 3:13 AM
0 · Reply
BB_88_
BB_88_ Oct. 17 at 7:41 PM
$NVCR 13.8 should crack shortly
0 · Reply
BB_88_
BB_88_ Oct. 17 at 7:26 PM
$NVCR bullish long term but took a 13.9 short in to close
1 · Reply
scotofool
scotofool Oct. 16 at 3:17 AM
$NVCR @AdamCrush wanker, no blokes wants this proper trash 25 or 15, defective harming, stop spreadings falsies, Roche me arse
0 · Reply
NeuroRad
NeuroRad Oct. 15 at 6:48 PM
$NVCR stars possibly aligning for this stock with positive catalysts in 2026 in combination with fed easing. I keep coming back to CEO 1 million open market purchase.
0 · Reply
AdamCrush
AdamCrush Oct. 15 at 2:12 PM
$NVCR acquisition at $25 by EU Pharma co Roche
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 14 at 1:54 PM
Change in share price of all commercial-stage oncology focused bios with market caps north of $300MM since last weeks close (using share prices this morning as of 9:40 AM). The XBI is off 2% where most in this peer group are off much more. $ZYME is clearly the biggest winner the last 5 trading days $ONC $GERN $NVCR SNDX & $AUTL are off the most in the peer group For information purposes only. This is not investment advice.
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 13 at 5:30 PM
$NVCR $SRRK $QURE $TMDX I've had a pretty good run in bios this year and decided it was time to once again make random (not just year end for tax purposes) donations to St. Jude's to share the wealth. Please remember there are kids suffering and families struggling to cope with cancer. St. Jude's makes a difference. ​5K donation made, more to come. Good fortune to all. https://www.stjude.org/donate/donate-to-st-jude.html?sc_icid=home-btn-donate-now
1 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 13 at 1:01 PM
$JFBR $NUKK $PPBT $SEDG $NVCR God for the peace deal & hostage return ☮️
1 · Reply
mohernx
mohernx Oct. 11 at 6:54 PM
0 · Reply
mohernx
mohernx Oct. 11 at 6:53 PM
$NVCR Dancing baby is on a buying mode again. Listening to the song "How deep is your Love" 10 nish is sweet
0 · Reply
scotofool
scotofool Oct. 9 at 6:18 PM
$NVCR blokes me trustys big coverups bad safety leaky soons, wait investors learn hiding proper cock-up, target 7
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 8 at 11:52 PM
$NVCR Keep on Truckin
0 · Reply
Stonkapedia
Stonkapedia Oct. 8 at 10:33 AM
$NVCR POS 💩
0 · Reply
nikitatrades
nikitatrades Oct. 7 at 10:24 AM
$NVCR is transitioning to a multi-indication co! Building on its $600M+ GBM biz, it expects 3 new launches by end of 2026: lung cancer (Optune Lua), pancreatic cancer (filed Aug '25), & brain mets. Goal: diversify revenue & path to profitability. 🚀 #Oncology #Investing Lung cancer launch is challenging (device in a drug world), but $NVCR is learning & adapting. The REAL excitement is pancreatic cancer—CEO's "favorite child." PMA submitted, approval expected mid-2026. PANOVA-4 Phase II data due Q1 2026 could be a catalyst. 🧠 #Biotech Strong financial position: $900M+ cash, convert debt to be paid off. Existing GBM biz is cash flow positive, growing mid-single digits. With 4 products soon, SG&A leverage is built—top-line growth should drive path to profitability. Trading at a discount to fundamentals. 💰 #NVCR
0 · Reply